echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Novel coronavirus pneumonia: 30 potentially effective mature drugs + 5 accelerated research and development drugs

    Novel coronavirus pneumonia: 30 potentially effective mature drugs + 5 accelerated research and development drugs

    • Last Update: 2020-02-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Due to the novel coronavirus (2019-nCOV) infection, the CDE of the State Administration of drug supervision has adjusted the registration and acceptance of drugs during the epidemic period, and other fields such as registration, receipt, declaration and consultation will be suspended except for the declaration of special products such as 2019-nCOV infection and pneumonia, and CDE can be contacted at any time In February 8th, the novel coronavirus pneumonia treatment plan was issued by the national health and Health Commission (the fifth version of the revised version) It is clear that there is no effective antiviral treatment In addition to the necessary supportive treatment, patients can try interferon alpha aerosol inhalation, oral lopinavir / ritonavir, or add ribavirin intravenous infusion At the same time, patients should avoid blind or inappropriate use of antibiotics, especially the combination of broad-spectrum antibiotics 30 novel coronavirus, which may be effective, was discovered in January 25th by the joint research team of China Academy of Sciences Shanghai Institute of Materia Medica and Shanghai University of science and technology 30 effective drugs for new coronavirus, including 12 kinds of anti HIV drugs, and Chinese herbal medicines such as Polygonum cuspidatum and Sophora Tonkin root, were found The specific list is as follows: Ninhydenavir, xaquinavir, lopinavir, kafezomi, ritonavir, ridcivir or rendisivir, azanavi, darunavir, tiranavir, fosanavir, enzatovir, preytovir, abakavir, bortezomi, etigway, malibavir or mambavir, retgevir, montelukast, deoxyturkish rhubarb, polydatin, Shandou Gen chalcone , disulfiram, Carmofur, shikonin, ebse, tideglusib, PX-12, tdzd-8, cyclosporin A, cinnamyl thiamine To speed up the research and development process of new candidate drugs, in addition, there are a number of domestic and foreign enterprises trying to carry out different degrees of cooperation to jointly seek more effective solutions 1 On February 5, the clinical trial for 2019-ncov was launched in Wuhan As of February 7, the clinical trial was adjusted for many times Professor Zhao Jianping, an expert of Hubei medical treatment group, released a new clinical grouping scheme, and now he is more inclined to severe patients The ratio of the former treatment group to the control group was 1:1, and the adjusted treatment group to the control group was 2:1, which means that the subjects had a 66% probability of receiving radcivir treatment 2 Ino-4800 vaccine on January 30, inovio pharmaceuticals, Inc (nsdq: iNO) and Beijing Aidi Weixin Biotechnology Co., Ltd jointly accelerated the development of 2019-ncov vaccine ino-4800 in China Innovio recently announced that the epidemic prevention Innovation Alliance (CEPI) has provided up to $9 million in funding to innovio to support innovio to pass the phase I human trial of ino-4800 in the United States to assess the safety and immunogenicity of the vaccine The cooperation aims to conduct a phase I trial in China with the technology of etivix and cooperate with the clinical development work of inovio in the United States Inovio and Edison will also work together to raise more funds and further work with large Chinese vaccine companies to speed up the testing of the INO-4800 in the future 3 On February 2, Guanhao Biotechnology Co., Ltd (hereinafter referred to as "Guanhao biology" with securities code of 300238) and ZY therapeutics Inc (hereinafter referred to as "ZY") signed a framework agreement on cooperation intention of nucleic acid vaccine project to jointly carry out the research and clinical project of new type pneumonia coronavirus mRNA vaccine (z-vaccirna) 4 Bdb-001 injection was approved for clinical trial On February 7, shutaishen (Beijing) biopharmaceutical Co., Ltd (hereinafter referred to as "shutaishen", securities code: 300204) received the approval for clinical trial of drugs, allowing bdb-001 injection to carry out clinical trials aimed at reducing the incidence of severe pulmonary inflammation and acute respiratory distress syndrome in 2019-ncov infected patients; 5 On February 9, Shenzhen Kangtai Biological Products Co., Ltd (hereinafter referred to as "Kangtai biological" with securities code of 300601) signed a strategic cooperation agreement with Aidi Weixin (Suzhou) biopharmaceutical Co., Ltd to jointly develop the new crown DNA vaccine.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.